We are Praxis Precision Medicines. We are a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for patients affected by central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, including patients and families impacted by rare genetic epilepsies. Our dedicated Epilepsy Franchise is comprised of neurologists, geneticists, scientists, and parents of children with SCN2A mutations. And like all parents, we are fighting to give our children the most fulfilling existence we can.
We’re excited to announce a new development related to our planned EMBRAVE study (PRAX-222), known as EMBRAVE, which is specifically designed for early onset children with gain-of-function SCN2A epilepsy. EMBRAVE (PRAX-222) is planned to launch later this year, and eligibility for that study may require three months of recent electroencephalogram (EEG) data as well as seizure diaries. Patients with early-onset SCN2A-DEE now have an opportunity to participate in a preliminary assessment of their condition called the SCN2A EEG Observational Study, which involves at-home collection of this information that could provide information that may facilitate later enrollment in EMBRAVE (PRAX-222)
We invite you to join us as we progress exciting new potential treatments through clinical development and team with our allies in the fight against this devastating disorder.
Program updates will be provided as new information is available about clinical trials, education, and resources to support the SCN2A community.